The "growing body of data" supporting superior outcomes versus conventional bupivacaine in "widely different" surgical settings further supports the view that sales growth of Pacira Pharmaceuticals' (PRCX) Exparel is poised for "meaningful acceleration" in 2019, Piper Jaffray analyst David Amsellem tells investors in a research note. The company is well positioned for sustainable annual double-digit growth, even amid the presence of Heron Therapeutics' (HRTX) HTX-011, adds the analyst. He reiterates an Overweight rating on Pacira with a $55 price target.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here